The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
Open accessAbstract
The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90. This promotes the polyubiquitylation and degradation of the pro-growth and pro-survival client proteins Bcr-Abl, mutant FLT-3, c-Raf, and AKT in human leukemia cells. HDAC6 is a member of the class IIB HDACs. It is predominantly cytosolic, microtubule-associated alpha-tubulin deacetylase that is also known to promote aggresome inclusion of the misfolded polyubiquitylated proteins. Here we demonstrate that in the Bcr-abl oncogene expressing human leukemia K562 cells, HDAC6 can be co-immunoprecipitated with HSP90, and the knock-down of HDAC6 by its siRNA induced the acetylation of HSP90 and alpha-tubulin. Depletion of HDAC6 levels also inhibited the binding of HSP90 to ATP, reduced the chaperone association of HSP90 with its client proteins, e.g. Bcr-Abl, and induced polyubiquitylation and partial depletion of Bcr-Abl. Conversely, the ectopic overexpression of HDAC6 inhibited LAQ824-induced acetylation of HSP90 and alpha-tubulin and reduced LAQ824-mediated depletion of Bcr-Abl, AKT, and c-Raf. Collectively, these findings indicate that HDAC6 is also an HSP90 deacetylase. Targeted inhibition of HDAC6 leads to acetylation of HSP90 and disruption of its chaperone function, resulting in polyubiquitylation and depletion of pro-growth and pro-survival HSP90 client proteins including Bcr-Abl. Depletion of HDAC6 sensitized human leukemia cells to HAA-HDIs and proteasome inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To further investigate the potential of acetylation to inhibit Hsp90 function, we used trichostatin A (TSA), which was shown to induce acetylation of Hsp90 in eukaryotes (17–20).”
From Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in Aspergillus fumigatus (2014) · cites this paper as [17]
In the citing paper
“HDAC6 was shown to be the deacetylase for a diverse set of substrates involved in tumourigenesis, such as HSP90, α-tubulin, cortactin and peroxiredoxins”
From A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth (2013) · cites this paper as Bali et al, 2005
In the citing paper
“HDAC6 knockout in mice does not lead to embryonic lethality”
From A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth (2013) · cites this paper as Bali et al, 2005
In the citing paper
“unlike other HDACs, inhibition of HDAC6 is believed not to be associated with severe toxicity”
From A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth (2013) · cites this paper as Bali et al, 2005
Citations
Cites
Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein
Hartl, F. U., & Hayer-Hartl, M. K. (2002) · Science · doi:10.1126/science.1068408 · Cited by 3,335
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,497
Stebbins, C. E., Russo, A. A., Schneider, C. B., Rosen, N. X., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,370
Felsenfeld, G., & Groudine, M. T. (2003) · Nature · doi:10.1038/nature01411 · Cited by 1,252
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,052
Heat-shock protein 90, a chaperone for folding and regulation
Picard, D. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012491 · Cited by 812
Research works printed but not linked: 5
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- Nimmanapalli, 2003, Cancer Res., 63, 5126
- Fuino, 2003, Mol. Cancer Ther., 2, 971
- Nimmanapalli, 2002, Cancer Res., 62, 5761
- Bagatell, 2000, Clin. Cancer Res., 6, 3312
Cited by
Sorted by citations
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Self-citationHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,277
Self-citationHistone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,194
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Self-citationLysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
Yang, X.-J., & Seto, E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.002 · Cited by 1,006
Self-citationThe world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 847
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Zhang, X. M., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J. M., Olashaw, N., Parsons, J. T., Yang, X., Dent, S., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 731
Self-citationDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 670
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C. C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
(2011) · PubMed Central · Cited by 560
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559
Drugging the Cancer Chaperone HSP90
Workman, P., Burrows, F. J., Neckers, L., & Rosen, N. X. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 531
HDAC6: a key regulator of cytoskeleton, cell migration and cell–cell interactions
Valenzuela-Fernández, A., Cabrero, J. R., Serrador, J. M., & Sánchez‐Madrid, F. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.04.003 · Cited by 510
Heat shock proteins: essential proteins for apoptosis regulation
Lanneau, D., Brunet, M., Frisan, E., Solary, É., Fontenay, M., & Garrido, C. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00273.x · Cited by 518
The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones
Li, J., Soroka, J., & Buchner, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.003 · Cited by 498
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 473
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 427
Self-citationNovel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Grant, S., Easley, C., & Kirkpatrick, P. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 417
An Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function
Scroggins, B. T., Robzyk, K., Wang, D., Marcu, M. G., Tsutsumi, S., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.008 · Cited by 413
Kwon, S., Zhang, Y., & Matthias, P. (2007) · Genes & Development · doi:10.1101/gad.461107 · Cited by 417
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
Boyault, C., Sadoul, K., Pabion, M., & Khochbin, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210614 · Cited by 397
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregatesPreprint
Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., Kwon, S. H., Garrido, C., Yao, T., Vourc’h, C., Matthias, P., et al. (2007) · Genes & Development · doi:10.1101/gad.436407 · Cited by 387
Targeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A. E., & Tsai, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 365
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes
Li, Y., Shin, D., & Kwon, S. H. (2012) · FEBS Journal · doi:10.1111/febs.12079 · Cited by 351
Catley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Self-citationHDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W., Venta-Perez, G., Erdjument‐Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 328
Mechanisms of Hsp90 regulation
Prodromou, C. (2016) · Biochemical Journal · doi:10.1042/bcj20160005 · Cited by 324
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 315
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. W., & Пили, Р. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 308
Self-citationHistone deacetylases 1 and 2 act in concert to promote the G1-to-S progressionPreprint
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 306
Post-translational modifications of Hsp90 and their contributions to chaperone regulation
Mollapour, M., & Neckers, L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.07.018 · Cited by 288
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 285
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions
Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 287
Weinert, B. T., Wagner, S., Horn, H., Henriksen, P., Liu, W. R., Olsen, J. V., Jensen, L. J., & Choudhary, C. (2011) · Science Signaling · doi:10.1126/scisignal.2001902 · Cited by 279
HDAC6 as privileged target in drug discovery: A perspective
Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105274 · Cited by 274
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0188 · Cited by 260
Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3 + T-Regulatory Cells
de Zoeten, E. F., Wang, L., Butler, K. V., Beier, U. H., Akimova, T., Sai, H., Bradner, J. E., Mazitschek, R., Kozikowski, A. P., Matthias, P., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05155-11 · Cited by 257
Self-citationHistone acetylation in gene regulation
Verdone, L. (2006) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/ell028 · Cited by 257
Richon, V. M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603463 · Cited by 240
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0547 · Cited by 231
Badros, A. Z., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O. G., Harris, C., Zwiebel, J. A., Wright, J. J., Espinoza‐Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231
Sydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 230
Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Chin, L., Olzmann, J. A., & Li, L. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783330692 · Cited by 233
Inhibitors of histone deacetylase as antitumor agents: A critical review
Mohammed, M., Chandrasekar, M., Jeyapal, G. P., & Nanjan, M. J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.005 · Cited by 231
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 229
Regulation of protein turnover by acetyltransferases and deacetylases
Sadoul, K., Boyault, C., Pabion, M., & Khochbin, S. (2007) · Biochimie · doi:10.1016/j.biochi.2007.06.009 · Cited by 222
Histone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion
Yang, Y., Rao, R., Shen, J., Tang, Y., Fiskus, W. C., Nechtman, J., Atadja, P. W., & Bhalla, K. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0644 · Cited by 226
Self-citationTargeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 229
Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
Carew, J. S., Medina, E. C., Esquivel, J., Mahalingam, D., Swords, R. T., Kelly, K. R., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 218
Histone deacetylase inhibitors and cell death
Zhang, J., & Zhong, Q. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1656-6 · Cited by 229
Hsp90, an unlikely ally in the war on cancer
Barrott, J. J., & Haystead, T. (2013) · FEBS Journal · doi:10.1111/febs.12147 · Cited by 225
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders
Butler, R. K., & Bates, G. P. (2006) · Nature reviews. Neuroscience · doi:10.1038/nrn1989 · Cited by 215
Histone Deacetylase 6 Regulates Growth Factor-Induced Actin Remodeling and Endocytosis
Gao, Y., Hubbert, C. C., Lu, J., Lee, Y.-S., Lee, J., & Yao, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00393-07 · Cited by 209
The ins and outs of tubulin acetylation: More than just a post-translational modification?
Perdiz, D., Mackeh, R., Poüs, C., & Baillet, A. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.014 · Cited by 224
Post-translational modifications of Hsp90 and translating the chaperone code
Backe, S. J., Sager, R., Woodford, M. R., Makedon, A. M., & Mollapour, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011833 · Cited by 208
Namdar, M., Perez, G., Ngo, L., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013754107 · Cited by 210
Yang, Y., Fiskus, W. C., Yong, B., Atadja, P. W., Takahashi, Y., Pandita, T. K., Wang, H., & Bhalla, K. N. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217692110 · Cited by 211
Self-citationTargeting HDACs: A Promising Therapy for Alzheimer's Disease
Xu, K., Dai, X., Huang, H., & Jiang, Z.-F. (2011) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2011/143269 · Cited by 218
Pratt, W. B., Morishima, Y., Peng, H., & Osawa, Y. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009250 · Cited by 206
Multiple roles of class I HDACs in proliferation, differentiation, and development
Reichert, N., Choukrallah, M.-A., & Matthias, P. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0921-9 · Cited by 194
Beckers, T. L., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T. M., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 191
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
Mai, A., & Altucci, L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.020 · Cited by 192
Chaperoning steroid hormone action
Picard, D. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.06.003 · Cited by 190
Rao, R., Fiskus, W. C., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P. W., Bradner, J. E., & Bhalla, K. N. (2008) · Blood · doi:10.1182/blood-2008-03-143644 · Cited by 192
Self-citationHistone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
Marks, P. A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.008 · Cited by 189
Lo, P., & Sukumar, S. V. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1879 · Cited by 191
Chaperone-dependent stabilization and degradation of p53 mutants
Müller, P., Hrstka, R., Coomber, D., Lane, D. P., & Vojtěšek, B. (2008) · Oncogene · doi:10.1038/sj.onc.1211010 · Cited by 183
Histone deacetylases—an important class of cellular regulators with a variety of functions
Hildmann, C., Riester, D., & Schwienhorst, A. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0911-2 · Cited by 182
Welsbie, D. S., Xu, J., Chen, Y., Borsu, L. A., Scher, H. I., Rosen, N. X., & Sawyers, C. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2216 · Cited by 182
Wang, Y., Fiskus, W. C., Chong, D. G., Buckley, K. M., Natarajan, K., Rao, R., Joshi, A., Balusu, R., Koul, S., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222133 · Cited by 179
Self-citationLi, Y., Zhang, T., Schwartz, S. J., & Sun, D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2008.12.002 · Cited by 182
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activityPreprint
Li, Y., Kao, G. D., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Qin, J., Phelan, C. A., & Lazar, M. A. (2006) · Genes & Development · doi:10.1101/gad.1455006 · Cited by 175
Mayer, M. P., & Breton, L. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.022 · Cited by 184
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T., & Comb, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c700185200 · Cited by 174
Gibbs, A., Schwartzman, J. A., Deng, V., & Alumkal, J. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908908106 · Cited by 174
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 174
Development of vorinostat: Current applications and future perspectives for cancer therapy
Richon, V. M., Garcia-Vargas, J. E., & Hardwick, J. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.002 · Cited by 168
p53-Mediated Molecular Control of Autophagy in Tumor Cells
Mrakovcic, M., & Fröhlich, L. F. (2018) · Biomolecules · doi:10.3390/biom8020014 · Cited by 170
Gao, Y., Hubbert, C. C., & Yao, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042754 · Cited by 167
Regulation of the mammalian heat shock factor 1
Naidu, S. D., & Dinkova‐Kostova, A. T. (2017) · FEBS Journal · doi:10.1111/febs.13999 · Cited by 174
Comprehensive lysine acetylomes emerging from bacteria to humans
Kim, G.-W., & Yang, X. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.10.001 · Cited by 167
Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection
Lubkowska, A., Pluta, W. W., Strońska-Pluta, A., & Lalko, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179366 · Cited by 168
Differentiation therapy of acute myeloid leukemia: past, present and future
Petrie, K. R., Zelent, A., & Waxman, S. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257aee · Cited by 161
Sabnis, G. J., Goloubeva, O. G., Chumsri, S., Nguyen, N., Sukumar, S. V., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 164
Metadata
- Authors
- Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E., & Bhalla, K.
- Affiliations
- Moffitt Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Novartis (United States) (US)
- Corresponding author
- Bhalla, Kapil
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 280
- Issue
- 29
- Pages
- 26729-26734
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2151445954
- Cited by
- 755
- References
- 42
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 10 · 2023: 9 · 2022: 23 · 2021: 21 · 2020: 38 · 2019: 33 · 2018: 32 · 2017: 28 · 2016: 34 · 2015: 40 · 2014: 45 · 2013: 42 · 2012: 47
- FWCI
- 19.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HDAC6, HSP90, HSP90 acetylation, LAQ824, panobinostat, BCR-ABL, alpha-tubulin deacetylation, polyubiquitination, Hsp90 client proteins, Akt, Raf-1, leukemia, K562 cells, proteasome inhibitors, siRNA knockdown
- MeSH terms
- Histone Deacetylase 6, Panobinostat, Acetylation, Antineoplastic Agents, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Leukemia, Neoplasm Proteins, Protein Binding, Molecular Chaperones, HSP90 Heat-Shock Proteins, K562 Cells, Ubiquitin, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
